Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

 ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential —

Basel, 29 May 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600 monotherapy and combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as part of a multi cohort study to evaluate the safety and efficacy of ANV600 in multiple cancer indications.

ANV600 uses a non-blocking anti-PD-1 antibody to target a powerful  IL-2Rβ/γ selective IL-2 agonist to tumor-specific T cells, resulting in their proliferation and increase of tumor-killing potential. ANV600 is designed to administer in combination with approved PD-1 checkpoint inhibitors, thus enabling optimal dosing of IL-2 agonism and PD-1 blockade to maximize therapeutic benefit.

“Approval to start our first-in-human clinical study of ANV600 represents an important step towards validation of our approach,” said Eduard Gasal, M.D., Chief Medical Officer of Anaveon. “In preclinical studies, ANV600 has demonstrated marked efficacy and a favorable safety profile.  We are eager to bring this potential treatment option to patients.”

In March 2024, Anaveon entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon’s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ENDS

Media contact:
JW Communications
Julia Wilson
Email: julia.wilson@anaveon.com
Tel: +44 (0)7818 430877

About Anaveon:

Anaveon is a biotechnology company located in Basel, Switzerland.  Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compounds, ANV419 and ANV600, are currently in clinical trials in solid tumors.

Find out more at anaveon.com

Latest News

29.05.2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential — Basel, 29 May 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug…
Read more
14.12.2023
Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces publication of ANV419 Phase I clinical data in the Journal for ImmunoTherapy of Cancer

— ANV419 delivers high dose IL-2 to patients with a good safety and tolerability profile —
Basel, December 14, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced the publication of updated clinical data from the ongoing Phase I study of ANV419…
Read more
01.11.2023
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

— ANV600 is a potent, cis-signaling, IL-2Rβ/γ agonist which efficiently expands intratumoral stem-like CD8+ T cells —
Basel, November 1, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting…
Read more
Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.
Accept